Loading company…
Suzhou, China biotechnology company developing small molecule drugs for cancer treatment, founded in 2011.
Teligene was established in 2011 and is based in Suzhou, China. Founded by Amgen's chief scientist Dawei Zhang, the company develops small molecule new drugs and anti-tumour therapeutics for cancer treatment. Its pipeline includes EGFR small molecule inhibitors Sutentinib, TL118 and Cernetinib. In February 2021 the company raised USD 93 million in pre-IPO funding.
Funding rounds, investors and people for this company come from licensed data. A free account shows the first rows of each section; an approved contribution opens every profile in full.
Sign in